Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

7.65
-0.7900-9.36%
Volume:1.24M
Turnover:9.93M
Market Cap:791.91M
PE:-1.46
High:8.23
Open:8.23
Low:7.63
Close:8.44
Loading ...

Intellia Therapeutics Shares Fall After Morgan Stanley Downgrade

MT Newswires Live
·
28 Jan

Update: Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, Cuts Price Target to $11 From $56

MT Newswires Live
·
28 Jan

Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, $56 Price Target

MT Newswires Live
·
27 Jan

Intellia Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
27 Jan

Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

TIPRANKS
·
27 Jan

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

Zacks
·
23 Jan

Intellia Doses First Patient in Phase 3 Trial of Potential Treatment for Hereditary Angioedema

MT Newswires Live
·
22 Jan

Intellia Therapeutics announces first patient dosed in Phase 3 NTLA-2002

TIPRANKS
·
22 Jan

Intellia Therapeutics Announces First Patient Dosed in the Haelo Phase 3 Study of Ntla-2002, an Investigational in Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

THOMSON REUTERS
·
22 Jan

Intellia Therapeutics Inc - Expects to Complete Enrollment in Phase 3 Study by H2 2025

THOMSON REUTERS
·
22 Jan

Intellia Therapeutics Inc: Expects to Submit a Bla in 2026 to Support Plans for a U.S. Launch in 2027

THOMSON REUTERS
·
22 Jan

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

GlobeNewswire
·
22 Jan

Intellia Loses 21.6% in a Week: How Should You Play the Stock?

Zacks
·
18 Jan

CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?

Zacks
·
17 Jan

Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates

Zacks
·
17 Jan

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), CareDx (CDNA) and Intellia Therapeutics (NTLA)

TIPRANKS
·
14 Jan

Intellia ATTR, HAE studies progressing as planned, says JPMorgan

TIPRANKS
·
14 Jan

Intellia Therapeutics: Strategic Initiatives and Clinical Progress Justify Buy Rating

TIPRANKS
·
14 Jan

Intellia Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
14 Jan

Oppenheimer Keeps Their Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
13 Jan